Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Famotidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 2/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 2/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 1.00 |
| ▸ | CA4 | P22748 | 2/20 | 1.00 |
| ▸ | CA6 | P23280 | 2/20 | 1.00 |
| ▸ | CA5A | P35218 | 2/20 | 1.00 |
| ▸ | CA7 | P43166 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | POU5F1 | Q01860 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 2/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Famotidine SCHEMBL39237 | 1.00 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL29384901 | 1.00 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL973 | 1.00 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL28032679 | 0.99 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL1863201 | 0.99 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL22127098 | 0.99 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL1863206 | 0.98 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL7119657 | 0.98 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL28528271 | 0.98 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL9817308 | 0.98 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043901-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING ENTEROVIRUSES WITH VAPENDAVIR SULFATE | Altesa BioSciences, Inc. (US) | 2026-02-26 | — | — | WO | claimed |
| US-20260048050-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING ENTEROVIRUSES WITH VAPENDAVIR SULFATE | Altesa BioSciences, Inc. (US) | 2026-02-19 | — | — | US | claimed |
| CN-118853094-A | Environment-friendly single-phase immersed cooling liquid with vegetable oil as base oil and preparation method thereof | 武汉泽电新材料有限公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2021183259-A1 | FAMOTIDINE AND FAMOTIDINE ANALOGS FOR CORONA VIRUS TREATMENT | Nanopharmaceutics, Inc. (US) | 2021-09-16 | — | — | WO | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| WO-2026043901-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING ENTEROVIRUSES WITH VAPENDAVIR SULFATE | Altesa BioSciences, Inc. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20260053745-A1 | METHODS OF PROPHYLAXIS OF CORONAVIRUS INFECTION AND TREATMENT OF CORONAVIRUSES | CUREMARK LLC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260048050-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING ENTEROVIRUSES WITH VAPENDAVIR SULFATE | Altesa BioSciences, Inc. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | APTARGROUP, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-12485094-B2 | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses | CUREMARK, LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090137645-A1 | Shelf-Stable Famotidine Granulates for Oral Suspensions | MIDLOTHIAN LABORATORIES, LLC (US) | 2009-05-28 | — | — | US | disclosed |
| US-20040156903-A1 | Metering and packaging of controlled release medication | MICRODOSE THERAPEUTX, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-1998040367-A1 | NOVEL THIAZOLE DERIVATIVES AND THEIR PREPARATION | ALBEMARLE CORPORATION (US) | 1998-09-17 | — | — | WO | disclosed |
| EP-0707492-A1 | H 2? ANTAGONIST-GASTROINTESTINAL MOTILITY AGENT COMBINATIONS | MERCK & CO. INC. (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001784-A1 | H2 ANTAGONIST-SUCRALFATE-ANTIFLATULENT COMBINATIONS | MERCK & CO., INC. (US) | 1995-01-19 | — | — | WO | disclosed |
| WO-1995001803-A1 | H2 ANTAGONIST-GASTROINTESTINAL MOTILITY AGENT COMBINATIONS | MERCK & CO., INC. (US) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | CACNG6, MC5R, CRH | HRH2 2084/4885SLC22A2 2282/4885CA12 1418/4885 |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | HRH2 3539/4885SLC22A2 776/4885CA12 282/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | HRH2 638/4885SLC22A2 3440/4885CA12 4339/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | HRH2 3539/4885SLC22A2 776/4885CA12 282/4885 |
| US-20260053745-A1 | METHODS OF PROPHYLAXIS OF CORONAVIRUS INFECTION AND TREATMENT OF CORONAVIRUSES | PRSS2, SPINT2, PRSS1 | HRH2 2286/4885SLC22A2 2092/4885CA12 784/4885 |
| US-20090137645-A1 | Shelf-Stable Famotidine Granulates for Oral Suspensions | KIT, GCGR, GCG | HRH2 7/4885SLC22A2 1860/4885CA12 4649/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | HRH2 875/4885SLC22A2 3570/4885CA12 4119/4885 |
| US-20260048050-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING ENTEROVIRUSES WITH VAPENDAVIR SULFATE | RPP30, EXOSC9, RPL30 | HRH2 1570/4885SLC22A2 1077/4885CA12 3849/4885 |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | GCG, VAPA, GABRG2 | HRH2 2029/4885SLC22A2 2161/4885CA12 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.